Cadila Healthcare receives USFDA approval for Ethacrynate sodium

Zydus Cadila has received final USFDA approval to market Ethacrynate sodium for injection, used to reduce swelling caused by various diseases.
The company will market the drug in the strength of 50 mg/vials. It will produce the drug at its formulations manufacturing facility in Moraiya, Ahmedabad. Ethacrynate sodium for injection is used to reduce swelling caused by various diseases including diseases related to the liver, kidney, congestive heart failure and cancer.

Company Profile : Cadila Healthcare Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*